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Telomeraseer stem cell theory opens up many new challenges and opportunities to identify
targets for therapeutic intervention. However, the majority of cancer related therapeutic studies rely upon
rodent models of human cancer that rarely translate into clinical success in human patients. Naturally
occurring cancers in dogs, cats and humans share biological features, including molecular targets, telomerase
biology and tumour genetics. Studying cancer stem cell biology and telomere/telomerase dynamics in the
cancer bearing pet population may offer the opportunity to develop a greater understanding of cancer
biology in the natural setting and evaluate the development of novel therapies targeted at these systems.
© 2009 Elsevier B.V. All rights reserved.1. Introduction: stem cells and cancer
Adult stem cells exist in essentially all mammalian tissues, and
contribute to tissue repair and organ maintenance by replacing
differentiated cells as they are lost through attrition or damage.
These cells are capable of self-renewal and can give rise to all cell
lineages of the tissue they reside in [1]. The loss of stem cell self-
renewal capacity underlies certain degenerative diseases and appears
to contribute to mammalian ageing [2]. However in long-lived
organisms, self-renewing, highly undifferentiated stem cells may
provide an attractive substrate for malignant transformation [3]. The
cancer stem cell theory suggests that cancer originates from adult
stem cells. Mutations in adult stem cells are more likely to have
tumourigenic consequences than if the same mutations occurred in
cells destined to die or differentiate [4]. For example, unrepaired
genetic alterations in stem cells will be inherited by self-renewing
daughter cells and hence these mutations will accumulate with
aging. The process of tumourigenesis will be further aided by
functional mutations that provide a growth or survival advantage
and therefore a positive selection for the mutant stem cell clone.
Further expansion of this stem cell clone and differentiation of
mutant daughter cells would lead to a heterogeneous population of
cancer cells, constituting a “tumour organ” (Fig. 1) [5]. Potent tumour
suppressor mechanisms, such as senescence and apoptosis, exist to
sense damaged stem cell genomes with malignant potential and limit
replicative expansion or terminate such clones, respectively. How-
ever, fully-ﬂedged cancer will result from the accumulation multiplell rights reserved.cancer-promoting events that enable cell immortality and bypassing
of tumour suppressor mechanisms [6].
Cellular immortalisation is a critical step in carcinogenesis,
enabling the cell to evade cellular senescence and acquire an
inﬁnite life span [7]. In the absence of immortalisation a cell may
obtain essential oncogenic hallmarks, including self-sufﬁcient
growth, insensitivity to antigrowth signals, and evasion of apopto-
sis, but could not proliferate indeﬁnitely [8,9]. This highlights that
senescence is an important tumour suppressor mechanism by
which cells can suppress aberrant growth by arresting cell
proliferation. At the molecular level, mechanisms that contribute
to a cell escaping senescence and becoming immortal include
genomic instability; telomere length stabilisation; epigenetic gene
silencing by selective promoter methylation; oxidative DNA damage;
inactivation of cell cycle regulatory genes such as p16INK4a, p53, RB
or p21WAF1; overexpression of cellular oncogenes such as cMYC or
BMI-1; and expression of viral oncogenes [7,10,11]. Telomere
shortening represents a cell intrinsic mechanism associated with
senescence. Telomeres cap the end of each chromosome, and in
most mammalian somatic cells, telomeres get progressively shorter
with each round of cell division until they reach a critically short
length. Upon which chromosomal ends become exposed and
activates DNA damage responses that mediate cell cycle arrest or
apoptosis [12,13]. In most cases, maintenance of telomere length is
required for immortalisation and arises early in tumour progression
[14]. In the absence of immortalisation a cell is unable to undergo
malignant transformation. Therefore further understanding of the
immortalisation process and how this applies to cancer stem cells
could provide novel early molecular targets for the treatment and
prevention of cancer.
Fig. 1. Schematic representation of tumour development. (A) Stem cells acquire a
mutation that provides a growth advantage. (B) Mutated stem cells can out grow non-
mutated stem cells by cell competition. (C) Selection of additional mutations gives rise
to the tumour organ consisting of a heterogeneous population of cancer cells.
Table 1
The similarities between human cancers and canine and feline cancers
Feature Comment
Incidence The incidence of cancer in dogs is reported to be 1 in
3–4 and 1 in 4–5 in cats, representing a potentially
large study population.
Histology The majority of human cancers are well represented in
the canine population including breast cancer,
melanoma, head and neck squamous carcinoma and
osteosarcoma. Dogs and men are the only mammalian
species where prostate carcinoma is recognised [16].
Biological behaviour As with human cancer, cancer in dogs and cats follows
similar clinical courses, including metastasis
Molecular basis of disease
and molecular targets
Many of the genetic abnormalities (e.g. p53) and
molecular therapeutic targets (e.g. receptor tyrosine
kinases) are represented across the species.
Responses to therapy For example the response to chemotherapy in NHL is
similar in people as it is in dogs and cats.
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standing of cancer biology into clinical practice has been the lack of
good pre-clinical models of cancer. In this review, we will focus on the
biology of cancer stem cells, telomeres and telomerase but suggest
that by adopting a comparative approach to studying these systems in
companion animal cancers, we may develop a pre-clinical model
system that is more relevant to human oncology than current rodent
models.
2. Comparative oncology
The development of rodent transgenic and xenograft tumour
models has allowed major advances in our basic understanding of
cancer biology in a very cost effective and timely fashion. However, a
near universal reliance on these models has highlighted some major
deﬁciencies. For example, implanted or induced tumours in xenograft
models do not always behave in the same biological way as the natural
parent tumour in humans, which is especially true of primary tumour
growth and metastasis. In addition, treatments that demonstrate
success in rodent models rarely translate into successful therapies in
human clinical trials, clearly indicating fundamental differences that
are difﬁcult to resolve without utilizing alternative models [15]. As we
move towards developing highly targeted therapies for speciﬁc cancertypes, these problems will become further exaggerated obviating the
need to combine rodent studies with comparative cancer studies in
other species to optimize the potential of developing the most
effective cancer therapies for people [16].
The term comparative oncology is often used to describe the inte-
gration of studies in naturally occurring cancers in animals to the
study of human cancer biology and therapy and the contribution of
comparative studies to our understanding of human cancer cannot be
overstated. Studies on avian, feline and bovine retroviruses under-
pinned the discovery of oncogenes and tumour suppressor genes and
contributed to the discovery of HTLV-1 inman [17]. Seminal studies on
the role of DNA papilloma viruses in carcinogenesis in cattle have
directly facilitated the development of the ﬁrst effective cancer
vaccines for cervical cancer in women [18]. In recent years, and with
the recognition of some of the disadvantages of deﬁned rodent
models, researchers have turned to naturally occurring tumours in
dogs and cats to provide further insights into this devastating disease.
3. Dogs and cats as model systems
The improved life expectancy of people through control of
infectious diseases and advances in public health has led to an
apparent increase in age-related diseases such as cancer and
osteoarthritis. A similar pattern has been observed in pet dogs and
cats through vaccination regimes for once fatal infectious diseases and
major advances in veterinary care. It is estimated that 1 in 3–4 dogs
will develop cancer (and around 1 in 5 cats), and with around 7
million dogs in the UK this represents an opportunity to exploit these
cancers in terms of identifying cancer-associated genes, studying
environmental risk factors, understanding tumour progression and
evaluating new therapies [19].
Naturally occurring cancers in dogs and cats share many features
with their human counterparts (Table 1). Importantly, cancers in
these species develop naturally and in the context of an intact
immune system where tumour, microenvironment and host are
syngeneic. For the most part tumour histologies observed in human
medicine are represented in both dogs and cats and share biological
behaviour [20]. Importantly, these observed similarities can be
supported with hard genetic evidence with the publication of the
canine genome and the increased portfolio of molecular tools (e.g.
canine-speciﬁc affytmetrix array) for this species [16,21]. It is
becoming clear that the molecular drivers for both companion
animal cancers and human cancers are analogous with near iden-
tical speciﬁc genetic changes in oncogenes and tumour suppressor
genes. As an example, a recently constructed syntenic karyotype
map between humans and dogs demonstrated strong similarities in
cytogenetic abnormalities in Non-Hodgkin Lymphoma (NHL) occur-
ring in both of these species [22].
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Hayﬂick and Moorhead originally observed that normal somatic
cells have limited proliferative capacity and cannot grow indeﬁnitely
in culture [23]. After a ﬁnite number of divisions, cells reach their
proliferative limit and enter “replicative senescence”. These cells are
phenotypically characterised by a large, ﬂattened morphology and
expression of the biomarker “senescence associated β-galactosidase”
[24]. Senescent cells are growth arrested in G1 phase of the cell cycle,
are incapable of synthesising DNA, and are unresponsive to growth
factors, yet are still metabolically active [10,11]. Subsequent studies
have shown that telomeres become progressively shorter with each
population doubling until they reach a critically short length and
induce replicative senescence [25]. Consequently, telomeres have
been eloquently described as “molecular clocks” that determines the
life span of a cell [26].
Telomeres are specialised nucleoprotein complexes that cap and
protect the end of every eukaryotic chromosome against chromoso-
mal fusion, recombination, and terminal DNA degradation. Telomeres
are composed of non-coding TTAGGG double strand repeats,
orientated 5′-to-3′ toward the chromosome and ending in a 3′
single-stranded G-rich overhang [27]. To prevent degradation by
exonucleases or recognition by the DNA damage machinery, the 3′
single-stranded overhang of telomeric DNA folds back into the D-
loop of duplex telomeric DNA to form a protective T-loop, which is
reinforced with telomere binding proteins [28,29]. In mammalian
cells, telomeres associate with the shelterin complex of six core
proteins: TRF1 (telomeric repeat-binding protein 1, also known as
TERF1), TRF2 (also known as TERF2), TIN2 (TERF1-ineracting nuclear
factor 2), POT1 (protection of telomeres 1), TPP1 (POT-1- and TINF2-
interacting protein), and RAP1 (transcriptional repressor/activator
protein) [28,30] (Fig. 2). Telomeres that can no longer protect the
end of chromosomes are said to be dysfunctional, and can arise by
several mechanisms including progressive telomere attrition, loss of
telomere binding proteins and direct telomeric DNA damage [31].
Dysfunctional telomeres can elicit potent DNA damage response
pathways [12].
The length of telomeres in somatic cells can vary remarkably
among individuals according to age, organ and proliferative history of
each cell, for example telomere length in human somatic cells ranges
from 5 to 20 kb [32]. During DNA synthesis and cell division, telomeres
shorten due to the inability of DNA polymerase to copy the extreme 5′Fig. 2. Telomere structure. Telomeres are composed of TTAGGG repetitive sequences
that terminate in a 3′ single-stranded overhang, which can invade the double stranded
region of the telomere and form a protective T-loopwith a single-stranded D-loop at the
invasion site. Telomeric DNA is complexed with the shelterin protein complex
composed of TRF1, TRF2, RAP1, TIN2, TPP1 and POT1. TPP1 and POT1 regulate the
access of telomerase to the telomeric subunit.ends of chromosomes, termed the ‘end replication problem’ [33].
Progressive telomere shortening represents a tumour suppressor
mechanism and is proposed to be one of the molecular mechanisms
underlying ageing, as critically short telomeres triggers replicative
senescence and loss of cell viability [32,34]. Although most somatic
cells have a ﬁnite number of cell divisions, some cells have evolved
mechanisms to circumvent telomeric attrition therefore allowing
continued proliferation [8,35]. The enzyme telomerase is able to
maintain telomeres by synthesising telomeric DNA. Telomerase is a
ribonucleoprotein complex consisting of an RNA template (TERC),
which contains a template region complementary to the telomeric
repeat sequence TTAGGG, and a reverse transcriptase catalytic subunit
(TERT). The telomerase holoenzyme binds to the telomere through
alignment of the RNA template region with the telomere repeat
sequence. The protein component acts as a reverse transcriptase and
catalyses the addition of telomeric repeats onto the ends of
chromosomes using the RNA subunit as a template [36–38].
Telomerase activity prevents replication-dependent loss of telomeres
and permits cells to overcome mammalian cell mortality. In agree-
ment, ectopic expression of human telomerase is sufﬁcient to stabilise
telomeres in normal human ﬁbroblast cells, bypass replicative
senescence and allow immortal cell proliferation [39,40].
In humans, telomerase activity is tightly regulated by expression of
the reverse transcriptase catalytic subunit (TERT). Telomerase is
essential for embryogenesis but is repressed upon tissue differentia-
tion during development and is absent from birth in most somatic
tissues [41]. Cell populations that continue dividing throughout life,
such as germ and stem cells, continue to express telomerase at
reduced levels to maintain self-renewal capacity. In fact, low levels of
telomerase activity have been found in some human adult stem cell
compartments, including haematopoietic stem cells (HSCs) [42–44]
and intestinal stem and progenitor cells in basal crypts [45]. Transient
upregulation of telomerase activity has been observed in committed
haematopoietic progenitor cells with increased cellular proliferation,
possibly to reduce the rate of telomere loss during periods of rapid cell
division and prevent premature telomere shortening. In more mature
cells, telomerase activity is repressed independently of proliferation
rate (Fig. 3) [46]. Signiﬁcantly, a majority of human cancer cell lines
and 85% of human cancers, encompassing a broad range of cancer
types, possess telomerase activity. By contrast, little or no telomerase
activity was detected in normal somatic tissues [47,48]. The expres-
sion of telomerase in a wide range of human cancers signiﬁes the
molecular mechanism by which most cancer cells gain immortality
and represents an exciting therapeutic target.
Reactivation of telomerase is an imperative step in immortalisation
of cancer cells and tumour progression. Currently the most commonly
used in vivo model used to study telomeres and telomerase activity is
the mouse. In mice, telomerase is present in all adult tissues and
telomere lengths aremuch longer relative to humans, ranging from 40
to 80 kb, which are commonly reduced to a humanised length prior to
experimentation by successive mTERC−/− intercrossing [49,50]. In
dogs, like humans, telomerase activity is upregulated in a majority of
cancers and is absent in normal adult tissues [8]. The canine Tert
promoter is similar to human promoter in structure and activity, and
there is good correlation between Tert expression and telomerase
activity in dog tissues [51,52]. Whilst the number of studies examining
canine tumours is relatively small, it is evident that telomerase is
present in the majority (N90%) of canine cancers and is absent from
most normal tissues [8,51,53–55].
Importantly, telomere lengths are comparable in size to humans,
and ageing canine ﬁbroblast cells undergo telomere attrition in
culture [51]. Human telomere and telomerase dynamics therefore
appear to be conserved in dogs (Table 2). Currently, very little is
known about the telomere length in canine tumours per se compared
to normal tissues as such studies are lacking. In general, human
tumour cells have shorter telomere lengths than normal cells and
Fig. 3. Telomerase activity in relation to cell growth and age. Germ cells and embryonic stem cells (ESC) have high levels of telomerase activity. In the developmental stage,
telomerase activity decreases and diminishes in most somatic cells after birth. Adult stem cells have a low level of telomerase that is upregulated in highly proliferative progenitor
cells. However this is insufﬁcient tomaintain their telomere length, rendering these cells mortal and prone to telomere shortening. Cancer stem cells may be derived from adult stem,
progenitor or somatic cells and may be immortal, having the ability to indeﬁnitely self-renew and proliferate (adapted from Hiyama and Hiyama [13]).
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divisions, due to telomere maintenance by the enzyme telomerase.
Some human tumour types (e.g. osteosarcomas [56], gliomas [57], soft
tissue sarcomas and astrocytomas [58]) have been shown to maintain
their telomeres by an alternative mechanism which has been termed
alternative lengthening of telomeres or ALT and proposed to occur via
homologous recombination. At present there is no conclusive
evidence for ALT in canine cancers although a recent report suggests
that this may occur in canine osteosarcoma [59].
5. Dysfunctional telomeres and tumourigenesis
As dysfunctional telomeres have lost their protective structure,
either through telomere attrition or disruption of telomeric bindingTable 2
Comparative telomere and telomerase biology
Species Telomere length Telomerase activity
Mouse N60 kb Ubiquitous
Human 15–20 kb Tumour tissue
Stem cells
Gonadal tissue
Activated white blood cells
Dog 15–20 kb Tumour tissue
Stem cells
Gonadal tissue
Activated white blood cellsproteins, they are recognised as damaged DNA and activate a DNA
damage response pathway [60] (Fig. 4). In mammals, uncapped
telomeres activate signalling cascades involving the protein kinases
ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia
and Rad-3 related). These kinases are recruited to telomeres and are
activated, leading to the phosphorylation of histone H2AX adjacent to
the site of DNA damage. Phosphorylated H2AX facilitates the focal
assembly of checkpoint and DNA repair factors, including 53BP1 (p53
binding protein 1), NBS1 (also known nibrin) and MDC1. The DNA
damaged foci around uncapped telomeres also promotes the ATM/
ATR dependent phosphorylation and activation of the transducer
kinases CHK2 and CHK1, which converge the signal on p53 [12,60].
The tumour suppressor protein p53 had been heralded as the
“guardian of the genome” for its role in preserving genome integrity
by regulating the expression of genes involved in growth arrest, DNA
repair and apoptosis in response to DNA damage [61,62].
In the context of replicative senescence, p53 induces cell cycle
arrest by stimulating expression of the cyclin-dependent kinase
inhibitor p21WAF1 [63,64]. In the G1 phase of the cell cycle the RB
(retinoblastoma) protein is hypophosphorylated, and in this state
binds to and sequesters the E2F family of transcription factors, which
promote S phase. Release of active E2F, which then leads to the
transcription of genes required for S phase progression, is mediated by
sequential phosphorylation of RB by cyclin D/CDK4 and cyclin E/CDK2
[65,66]. p21WAF1 inhibits cyclin E/CDK2, maintaining the RB-E2F
complex, consequently preventing S phase entry and sustaining a G1
arrest [67,68]. Mutation of the p53 gene is the most tumour-related
Fig. 4. Telomere dysfunction activates the p53 and RB pathways. Progressive telomere
shortening or uncapped telomeres initiate a DNA damage response. Resulting in
activation of ATM and ATR, and the downstream kinases CHK1 and CHK2, and
phosphorylation of p53. Activated p53 inhibits tumourigenesis by transcriptionally
upregulating genes that mediate cellular senescence and/or apoptosis. The p16INK4a/
RB pathway inhibits cellular proliferation and is also activated by telomere dysfunction.
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cancers [69]. The role of p53 in canine and feline tumours has also
been extensively studied, and probably plays a major role in
carcinogenesis in these species [70,71]. Functional inactivation of
p53 in response to telomere dysfunction would provide a passive
environment that tolerates proliferation and survival of genomically
unstable cells, and may aid cancer progression. p16INK4a is also a
cyclin-dependent kinase inhibitor that maintains RB in a hypopho-
sphorylated state [72], is markedly increased in senescent cells, and
has been implicated in maintaining the senescence state [72,73].
When these cell cycle checkpoint proteins are inactivated by antisense
oligonucleotides [74] or viral oncoproteins [75], cells bypass senes-
cence and continue to proliferate. This leads to high cellular levels of
genomic instability and induces p53-independent induction of cell
death [76]. Few cells escape from this crisis period and those that do
acquire the ability to stabilise telomeres, mainly through the
reactivation of telomerase [40,77].
Uncapped telomeres are highly recombinogenic and can lead to
improper chromosomal fusions [12,78]. During mitosis of the cell
cycle the fused chromosomes will be separated and broken by the
anaphase bridge, generating new telomere free chromosomal ends
which will fuse and break again during the next round of cell division
[79,80]. Hence telomere dysfunction can initiate a cascade of
chromosomal gains, losses and translocations, creating novel chro-
mosomal variants with each cell division [81,82]. Chromosomal
instability is characteristic of tumourigenesis [81]. In human cancer,
telomere shortening has been observed in very early tumour stages,
indicating that tumours arise from cells with telomere dysfunction
[83]. To evaluate the contribution of telomere dysfunction to
tumourigenesis, telomerase deﬁcient (mTerc−/−) mice, which lackthe RNA subunit Terc, were generated [78]. Studies in mTerc−/−
mice showed that telomere shortening enhanced tumour initiation
but suppressed tumour progression [80,84,85]. This is not surprising
considering that telomere dysfunction induces the DNA damage
pathways leading to senescence. In vitro experiments have shown that
deletion of p53, in contrast to p16INK4a deletion, can extend the life
span of cells with critically short telomeres by bypassing senescence
and increase susceptibility to oncogenic transformation by Myc and
Hras [60]. In vivo, mTerc−/−, p53−/−mice do not have an extended
life span compared to mTerc−/− mice due to early tumour
development. These tumours exhibit high rates of chromosomal
instability [86,87]. Interestingly, the tumour spectrum of mTerc−/−,
p53+/− mice resembled the high incidence of epithelial cancer in
ageing humans [86], signifying that loss of p53 co-operates with
telomere dysfunction to induce chromosomal instability and
tumourigenesis.
6. Telomeres, telomerase and stem cells
Embryonic stem cells (ESC) are capable of indeﬁnite self-renewal,
can differentiate and contribute to the germ line. Experiments in both
mouse ESCs [88] and human ESCs [89] have shown that these cells are
unique in that they can proliferate indeﬁnitely in culture, do not
undergo replicative senescence and remain untransformed over
multiple passages. In contrast tomalignant tumour cells, ESCs respond
to growth stimulation and inhibition signals, have a normal karyotype,
and are able to differentiate in to non-immortal cells that undergo
telomere shortening and replicative senescence [90]. ESCs are
inherently immortal, which is lost upon differentiation into somatic
cells, and express high levels of TERTand correspondingly display high
levels of telomerase activity. During differentiation down regulation of
telomerase activity has been correlated with histone deacetylation
and DNA methylation of the TERT gene [91]. Interestingly, cell cycle
regulatory pathways in ESCs may signiﬁcantly differ from those in
differentiated somatic cells, as mouse ESCs were shown to have a
defective Rb pathway and a nonresponsive p53 pathway [92–94]. The
p53-dependent checkpoint was compromised as p53was sequestered
in the cytoplasm and unable to induce the transcription of genes
necessary to induce cell cycle arrest, signiﬁcantly the p53 pathway
was restored after differentiation [92].
Although telomerase activity is very high during embryonic
development this is downregulated in a majority of adult tissues
after birth, with the exception of the adult stem cell compartments
and cells that undergo rapid expansion, such as lymphocytes or skin
keratinocytes [41] (Fig. 3). Adult stem cell compartments are
important in the homeostatic maintenance of many organs, including
organs with lower turn-over rates such as the brain and pancreatic
islets. Stem cells in several tissues are maintained mainly in a
quiescent state and undergo low but constant rates of cell turnover
during their lifetime, which may require telomerase expression to
prevent telomere shortening [4]. However, adult stem cells only
maintain low levels of telomerase activity and this is not sufﬁcient to
maintain telomere length during stem cell ageing [95]. Although the
presence of telomerase in these cells suggests that telomerase is
important for stem cell function and organism ﬁtness. Evidence that
telomere shortening of stem cell compartments plays a causative role
in ageing comes from the study of human diseases associated with
mutations in the telomerase core components. Mutations in the TERC
gene have been associated with the rare genetic disorders dysker-
atosis congenita [96] and aplastic anaemia [97]. These diseases are
characterised by premature loss of tissue regeneration due to loss of
telomerase activity and telomere shortening, stem cell exhaustion,
bonemarrow failure and premature death [96,97]. Studies in Terc−/−
mice have shown that telomere shortening reduces stem cell
function and is associated with impaired organ homeostasis of high
turn-over organs, reduced life span, impaired organ regeneration and
Fig. 6. The fate of stem cells with heritable DNA damage. Different DNA lesions are
associated with each outcome as indicated.
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expression of Tert in transgenic mouse models results in increased
tumourigenesis [102–104], signifying that ageing maybe the evolu-
tionary consequence of cancer protection (Fig. 5).
Telomerase activity has been implicated in both cancer and
ageing. These important biological processes have been proposed to
share common aspects of biology, in that they are both stem cell
diseases resulting from a defect or decline in regenerative capacity
and organ homeostasis. DNA damage may accumulate in self-
renewing stem cell compartments with increasing age until normal
stem cell biology is perturbed. Tumour suppressor mechanisms are
activated to remove damaged cells by either apoptosis or senes-
cence. Apoptosis of stem cells may have less severe effects on
regenerative potential of an organ than senescence. For example,
apoptotic cells can be cleared from the stem cell niche, allowing
viable stem cells to self-renew, replace damaged cells and facilitate
regeneration. However senescent cells continue to occupy the niche
and prevent replenishment of the stem cell compartment. Therefore
senescence may enhance stem cell attrition and the appearance of
age-related phenotypes. If oncogenic mutations accumulate, self-
renewing clones that contain such lesions might undergo positive
selection, leading to cancer (Fig. 6). Hence, cancer and ageing
maybe related endpoints of DNA damage accumulation in adult
stem cell compartments.
7. Cancer stem cells
The cancer stem cell theory has challenged the accepted paradigm
of tumourigenesis, where any cell in the body has the potential for
malignant transformation. The clonal evolution model of cancer
postulates that mutant tumour cells with a growth advantage are
selected and expanded, with all cells in the resulting tumour having
similar potential for regenerating tumour growth (Fig. 7A, B) [105]. In
conﬂict with this model, the bulk of cells in an organ have a ﬁnite life
span dictated by telomere attrition [106], therefore how does a cell
survive long enough to acquire the number of mutations required for
malignant transformation? Also the majority of therapeutic
approaches aimed at eliminating tumour cells are based on the clonal
evolution model. The limited effects of these conventional therapies
suggest that tumour cells include a resistant population of cells
responsible for tumour initiation, development, growth and reoccur-
rence. The discovery of a rare subset of cells with stem cell qualities in
acute myeloid leukaemia, that could induce leukaemia when
transplanted into immunodeﬁcient mice, has revolutionised the way
tumourigenesis is viewed and formed the foundation of the cancerFig. 5. Telomerase expression effects ageing and cancer. In the Tert transgenic mouse
model where Tert is overexpressed, the ageing phenotype is suppressed but there is an
increase in tumourigenesis.stem cell model [107]. In the cancer stem cell model, tumour
development, like the normal development of a tissue, relies upon a
subset of tumour cells that have ability to self-renew and generate the
diverse cells that comprise the tumour (Fig. 7C) [5]. Only those cells
within the tumour that can self-renew and differentiate are called
cancer stem cells. Therefore cancer stem cells can expand the cancer
stem cell pool and differentiate into cancer progenitor cells by
symmetric and asymmetric division, respectively. Consequently,
daughter cells lacking stem cell qualities will have only limited
proliferative potential but constitute the bulk of a tumourmass. In this
model, a tumour can be viewed as a heterogeneous and regenerative
tissue, where cancer stem cells are responsible for initiation and
maintenance of the cancer. This provides an explanation for
traditional chemo- and radiotherapies which often shrink the tumour
bulk but do not completely eradicate it, indicating that conventional
therapies cannot effectively target cancer stem cells embedded within
a given tumour mass.
The ﬁrst evidence for the existence of cancer stem cells came from
acute myeloid leukaemia. Bonnet and Dick isolated a rare subpopula-
tion of cells with the surface marker expression pattern of CD34+/
CD38−, characteristic of haematopoietic stem cells, from patients
with acute myeloid leukaemia [107]. Despite being small in numbers
(0.2% of the tumour population), these were the only cells that could
induce leukaemia phenotypically identical to the parent tumour after
transplanting them into non-obese diabetic severe combined immu-
nogenicity (NOD-SCID) mice. Cells with the typical leukaemia
phenotype CD34+/CD38+ were not capable of initiating tumour
development. From these observations and the hierarchical cell proﬁle
of leukaemia, reminiscent of haematopoiesis, Bonnet and Dick
concluded that malignant transformation occurs in the haematopoie-
tic stem cell and gives rise to leukaemic stem cells [107].
More recently cancer stem cells have been demonstrated in solid
tumours. The ﬁrst solid tumour from which cancer stem cells were
identiﬁed and isolated was breast cancer. Al-Hajj et al. [108]
described a CD44+/CD24− cell population that was signiﬁcantly
enriched for tumour initiation. Human breast tumour samples were
found to be heterogeneous in surface antigen expression, when
different populations were injected into NOD-SCID mice, only cells
Fig. 7. Models of tumour formation. (A) A normal cellular hierarchy comprising of adult stem cells at the apex, which generate progenitor cells, ultimately yielding all mature cell
types that constitute that particular tissue. (B) In the clonal evolution model all cells have the same tumourigenic capacity and any cell can initiate and maintain a tumour. (C) In the
cancer stem cell model, only cancer stem cells can generate a tumour due to its self-renewal and proliferative capacity. Cancer stem cells can also give rise to mutated progenitor and
mature cells that constitute the bulk of the tumour, and account for tumour heterogeneity.
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contained multiple cell types, similar to the original tumour,
indicating that CD44+/CD24− cells were not only capable of self-
renewal but also of generating a range of progeny [108]. Subse-
quently, CD133 was found to mark cancer stem cells in different
types of brain tumours including glioblastoma, medullablastoma, and
ependymomas [109–111]. CD133 is a cell-surface marker previously
shown to be expressed on neural stem cells [112]. However, CD133
has also been utilized to isolated and identify cancer stem cells in
colorectal [113,114] and pancreatic carcinomas [115], and has been
implicated as a common stemness marker in cancer stem cells with
different origins [116]. Cancer stem cells have also been identiﬁed inbladder [117], head and neck squamous cell carcinomas [118], bone
sarcomas [119], melanomas [120], retinoblastomas [121], prostate
[122], hepatic [123] and lung tumours [124].
The exact origins of cancer stem cells may vary. They could arise
from the malignant transformation of a normal stem cell that has
accumulated oncogenic mutations over time. Many of the attributes of
normal stem cells make them attractive candidates for malignant
transformation into cancer stem cells, they are programmed for self-
renewal and differentiation, and they persist and continue to divide
for the lifetime of the host, allowing them opportunity to amass
oncogenic lesions that lead to transformation. In support of this
model, isolated cancer stem cells share the same cell-surface marker
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Alternatively, the original tumour cell could be a more differentiated
cell that has acquired stem cell characteristics by mutation and
dedifferentiation [125]. The recent demonstration that adult ﬁbro-
blasts can be reprogrammed into pluripotent ES-like cells by
expression of four genes Oct3/4, Sox2, c-Myc, and Klf4 [126], raises
the possibility that expression of these stem cell factors and speciﬁc
oncogenes could induce a dedifferentiated state in cancer cells. These
factors and additional ESC speciﬁc genes have been shown to be highly
expressed in poorly differentiated breast, glioblastoma and bladder
carcinomas [127], suggesting that cancer cells may utilize the newly
identiﬁed “iPS reprogramming” mechanism [126] to obtain stem cell
characteristics, bypass senescence and gain immortality.
The ability of a cancer stem cell to initiate and drive tumourigen-
esis may be inﬂuenced by its niche environment, which is important
for normal stem cell function. The stem cell niche is an anatomical
compartment that provides signals to stem cells, via secreted and
cell-surface molecules, to control the rate of stem cell proliferation,
determine the fate of daughter cells, and protect stem cells from
exhaustion and death [128]. There is compelling evidence that the
tumour microenvironment promotes and sustains abnormal cell
growth of cancer cells. In the brain, both normal neural stem cells and
cancer stem cells are found in the region with a high capillaryFig. 8. Isolation of tumour initiating cells using the classical sphere assay and FACS analysis
conditions using serum-starved semi-solid media. Spheres form in ∼7–10 days and express e
small “side” population of cells that have an enhanced ability to exclude dyes, such as Hoechs
(C) The addition of Verapamil demonstrates loss of the side population by drug inhibition odensity, and the main component of these niches is endothelial cells.
Transplantation human medullablastoma cells with or without the
surrounding endothelial cells into NOD-SCID mice both caused
cancer, but co-transfection with the niche cells enhanced the tumour
size and growth rate [129]. Furthermore, expression proﬁling of
stromal cells that are associated with human basal cell carcinomas
demonstrated that tumour associated stroma, but not stroma
associated with normal skin, expresses secreted factors that block
the differentiation of epithelial cells within the tumour [130]. These
studies highlight an intricate relationship between the niche and
cancer stem cells.
8. The canine and feline model systems
Mechanisms of tumour development appear to be conserved
between human and dogs. Canine “cancer stem cells” have been
successfully isolated from osteosarcomas and have been shown to
express embryonic stem cell markers Oct 3/4 and Nanog, which are
involved maintenance of pluripotency [131]. Similar cancer stem cell
populations have been isolated from mammary carcinoma, mela-
noma, and haemangiosarcoma (unpublished results). In addition,
feline mammary tumour and squamous cell carcinoma initiating cells
have been identiﬁed from cell lines and clinical cases [132]. These cells. (A) Single cells from cell lines and clinical cases are cultured in non-adherent culture
mbryonic stem cell markers including Oct4 and Nanog. (B) FACS can be used to identify a
t 33342, potentially through expression of the ATP binding cassette protein transporters.
f efﬂux of Hoechst 33342.
Fig. 9. The integration of canine studies into human clinical drug development (adapted
from Paoloni and Khanna [176]).
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FACS analysis (Fig. 8) and interestingly have demonstrated reduced
sensitivities to both chemotherapy and radiation [132]. On a practical
level, there aremany advantages of utilizing dogs and cats in the study
of cancer stem cell biology:
• Access to biopsy material from clinical naive animals allows
interrogation of the cancer stem cell theory in the natural setting.
• Access to post-mortem material allows for close monitoring and
follow-up of clinical cases.
• Dogs and cats represent a pre-clinical model system to assess
therapeutics targeted to cancer stem cells.
9. Integrating canine and feline models to develop new therapies
With the evolution of the cancer stem cell theory, investigators
have focused on potential therapeutic targets including signalling
pathways and mechanisms that contribute to drug resistance (Table 3
and Refs. [133–175]). Molecular mechanisms that regulate critical
functions in normal stem cells, including self-renewal and prolifera-
tion, have been shown to be deregulated in human cancers. The
tumour suppressor proteins that inhibit tumour proliferation or regu-
late cellular responses to DNA damage, such as p53, PTEN, p16INK4a
and ARF, may also block stem cell self-renewal [106].
In preceding sections we have described the biological similarities
between cancers in humans and companion animals (dogs and cats).
In addition to providing a newmodel system to study cancer stem cell
biology, the biological similarities between the species may predictTable 3
Potential therapeutic targets based upon cancer stem cells and telomerase
Therapeutic strategy Comment
Improving
radiosensitivity
Inhibition of the checkpoint kinases CHK1 and CHK2 may
reduce radioresistance of CD133+ cells to levels
comparable to CD133− cells.
Signalling pathways Hedgehog, Notch and Wnt/β-catenin pathways regulate
stem cell self-renewal and may offer therapeutic targets.
Inhibition of Hedgehog-Gli1 with cyclopamine in mice
with highly aggressive glioblastoma led to a reduced
proliferation of CD133+ cells and prolonged survival
of the animals [148].
Cyclopamine was also able to cause tumour reduction in
mouse models of pancreas and prostate cancer [149,150].
Targeted disruption of the Notch pathway by inhibition
of γ-secretase with GSI-18 led to a reduction of CD133+
cells, slower tumour growth and apoptosis in the
medullablastoma, in vitro [151].
Wnt/β-catenin signalling was shown to be essential for
sustaining skin cancer stem cells but not normal
epidermal stem cells, this distinction may enable speciﬁc
targeting of cancer stem cells in squamous cell
carcinoma [127].
Targeting the
stem cell niche
However a combination of anti-angiogenic therapy and
chemotherapy may deregulate the niche and sensitise
cells to chemotherapy.
Telomerase targeting GRN163L is a modiﬁed oligonucleotide complimentary
to TERC and is currently in clinical trials [154].
G-quadruplex inducing agents, including RHPS4 and
BRACO19 [158,159]. The G-rich strand of telomeric DNA
can fold into a four stranded G-quadruplex, stabilisation
of which perturbs telomere function.
As TERT is expressed in the majority of human cancers,
it has been identiﬁed as a general tumour antigen.
Promoter directed therapy offers an elegant system
by which gene expression can be targeted to cells,
which the promoter is switched on.
Recently, telomerase-dependent conditionally replicative
adenoviral vectors have been developed [167].
Cancer stem cells are thought to have a greater resistance to either chemotherapy
(through the expression of active transport mechanisms or expression of anti-apoptotic
proteins) or radiotherapy (through enhanced DNA damage response pathways). This
table illustrates some potential alternative approaches.similarities in treatment responses between canine, feline and human
cancers [176]. The continued evolution and validation of the cancer
stem cell model demands re-evaluation of conventional cancer
therapies. Chemo- and radiotherapy are based on the assumption
that all cells with in a tumour are the same, and although these
approaches do signiﬁcantly reduce the tumour mass, progression
and/or relapse do occur and could be due to the persistence of
resistant cancer stem cells. A two-pronged strategymay be required to
remove both tumour initiating cells and tumour maintaining cells. To
develop such therapies the molecular mechanisms of resistance must
be established and circumvented, and novel pathways in cancer stem
cells must be evaluated. It is quite possible that the study of cancer
stem cell biology and potential therapeutic strategies in dogs and cats
may facilitate the rapid translation into human clinical trials.
Classical drug development follows a linear pathway from mouse
to phase 1, 2 and 3 clinical trials in human subjects. However, many
drugs that show efﬁcacy in mouse models often fail in human clinical
trials because of either a lack of efﬁcacy or unacceptable toxicity [15].
This highlights the potential problems of a reliance on rodent models
and makes drug development costly and inefﬁcient. The natural
canine or feline models may overcome some of these shortcomings
because their tumours demonstrate similar genomic instability and
heterogeneity to human cancers and may also allow key biologicalTable 4
The potential disadvantages of utilizing natural models
Issue Comment
Species differences There may be species variation in drug sensitivity.
Cancer types Although most human cancer types are represented in
the dog, the dog tends to get more mesenchymal and
lymphoid tumours. The incidence of epithelial cancers
is lower in dogs and trials may take longer to conduct.
Regulatory issues There is variation in this between Europe and the USA,
but studies in dogs and cats are closely regulated by
individual governments and all studies require ethical
and scientiﬁc approval.
Inbred vs. outbred It has been suggested that the “inbred” nature of dogs
does not lend itself well to cancer studies reﬂecting an
outbred population. In fact the germline genetic
diversity of a population of dogs with a given cancer is
similar to the diversity seen in well mixed human
populations.
Cost It is more expensive to conduct trials in dogs and cats
than in mice. However, considering the potential of
drug failure going directly from mouse studies into
human studies, the use of dogs and cats could
potentially save the pharmaceutical industry many
millions of dollars.
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human models alone.
There are several examples where dogs have provided key
insights into cancer biology and therapy [92,177–179]. In a recent
paper by Paoloni and Kahnna [176] the authors suggest that the dog
model could be integrated into the current linear drug development
model. In this approach, studies of novel compounds could be
performed in pet dogs with cancer and better inform both early
drug development parameters (activity, toxicity, pharmacokinetics
and pharmacodynamics) and later parameters such as dose,
schedule, biomarkers and the effects of combining drug strategies
(Fig. 9). In the development of biologics or small molecules that
target telomerase or cancer stem cell pathways, this could be an
essential step to streamline drug development. The translational
opportunities could be further broadened to go beyond observa-
tional studies and include:
• Detailed biological studies utilizing information from the canine
genome project and canine-speciﬁc molecular tools.
• Utilization of study interventions that would be difﬁcult to do in
human oncology (e.g. serial biopsy samples).
• Identiﬁcation of surrogate markers, or surrogate or biological
endpoints.
• Utilization of advanced in vivo imaging technologies such as PET-CT.
Some of these concepts of comparative oncology have been
adopted in the United States through the comparative oncology
programme of the NCI, and a number of studies have already been
performed utilizing canine models [176].
10. Future directions
The study of telomerase and cancer stem cell biology in both dogs
and cats offers two opportunities. Firstly, cancer is common in these
species and, as with human medicine, surgery, chemotherapy and
radiation are still the only realistic treatment options. The identiﬁca-
tion of therapeutic targets in these species may inform better and
safer drug development for dogs and cats. Secondly, parallel studies on
cancer stem cell biology between relevant models (dog, cat, human)
may offer an opportunity to integrate veterinary-based drug studies
into human drug development. There is no doubt that the rodent
model is very efﬁcient and very useful, and the authors are not
advocating exchanging this model for dogs and cats. There are equally
some drawbacks of using natural models (Table 4). However, the
drawbacks of rodent models need to be recognised and the potential
of natural models should be explored as a complimentary approach.
To develop therapies based upon a greater understanding of cancer
biology, one must consider:
• Are rodent models appropriate to evaluate novel therapies?
• Are classical linear phase 1, 2 or 3 clinical trials in people appropriate
to establish biological endpoints?
• Can studies on the naturally occurring cancers in dogs and cats
answer questions that cannot be answered in human or murine
studies alone?
• Would the integration of studies in cats and dogs into human clinical
studies help to make drug development more efﬁcient and less
costly.
The answers to these points will vary depending on the cancer
under study and the biological question being posed. However, the
studies that have been performed through the NCI suggest that
naturally occurring cancers in dogs provide us with a unique
opportunity to advance cancer biology and therapy. Studies should
continue to focus on speciﬁc biological questions and the availability
of canine and feline tumour banks, alongside species-speciﬁc reagents
should allow us to achieve this. The prospect of developing drugs
which target key pathways in either telomerase biology or cancerstem cells lends itself well to this and will allow better design of
human clinical trials.
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